ZYDUS PHARMS Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ZYDUS PHARMS, and what generic and branded alternatives to ZYDUS PHARMS drugs are available?
ZYDUS PHARMS has two hundred and seventy approved drugs.
There are twenty-three tentative approvals on ZYDUS PHARMS drugs.
Drugs and US Patents for ZYDUS PHARMS
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Zydus Pharms | CISATRACURIUM BESYLATE | cisatracurium besylate | INJECTABLE;INJECTION | 212171-001 | Nov 4, 2019 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
Zydus Pharms Usa Inc | GABAPENTIN | gabapentin | TABLET;ORAL | 078926-001 | Feb 11, 2011 | AB1 | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
Zydus Pharms | LENALIDOMIDE | lenalidomide | CAPSULE;ORAL | 210154-002 | Sep 12, 2022 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for ZYDUS PHARMS drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | for Injection | 200 mcg/vial | ➤ Subscribe | 2015-05-01 |
➤ Subscribe | for Injection | 100 mcg/vial and 500 mcg/vial | ➤ Subscribe | 2015-04-14 |
➤ Subscribe | Delayed-release Tablets | 20 mg | ➤ Subscribe | 2015-06-03 |
Similar Applicant Names
Here is a list of applicants with similar names.